Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to -$5.7 million.

  • Karyopharm Therapeutics' Change in Receivables fell 46314.23% to -$5.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.6 million, marking a year-over-year decrease of 22060.99%. This contributed to the annual value of -$4.6 million for FY2025, which is 22060.99% down from last year.
  • Karyopharm Therapeutics' Change in Receivables amounted to -$5.7 million in Q4 2025, which was down 46314.23% from -$1.1 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Change in Receivables' 5-year high stood at $6.9 million during Q2 2024, with a 5-year trough of -$11.9 million in Q1 2023.
  • Its 5-year average for Change in Receivables is -$310400.0, with a median of $89500.0 in 2021.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Change in Receivables surged by 35861.27% in 2022, and later tumbled by 821925.93% in 2023.
  • Karyopharm Therapeutics' Change in Receivables (Quarter) stood at $3.7 million in 2021, then tumbled by 96.4% to $135000.0 in 2022, then tumbled by 8219.26% to -$11.0 million in 2023, then soared by 90.77% to -$1.0 million in 2024, then tumbled by 463.14% to -$5.7 million in 2025.
  • Its Change in Receivables was -$5.7 million in Q4 2025, compared to -$1.1 million in Q3 2025 and -$2.3 million in Q2 2025.